UGUri Galili

Uri Galili

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Uri Galili has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • AGI-134, a fully synthetic α-Gal-based cancer immunotherapy: Synergy with an anti-PD-1 antibody and pre-clinical pharmacokinetic and toxicity profiles.

    by Sascha A. Kristian, Stephen M. Shaw, Kim Wigglesworth, Jenny Middleton, Melanie S. Glossop, Giles Francis Whalen, Robert Old, Uri Galili, Mike Westby, Chris Pickford

    3083 Background: Unlike virtually all non-primate mammals, humans lack α-Gal (Gal-α-1,3-Gal-β-1,4-GlcNAc) epitopes and produce antibodies against α-Gal-positive antigens. Anti-α-Gal (anti-Gal) antibodies are among the most abundant antibodies in humans and responsible for hyper-acute rejection of α-Gal-positive xenotransplants. Studies using rabbit-derived α-Gal glycolipids provided a preclinical proof of principle for α-Gal glycolipids as cancer immunotherapy, inducing a CD8+ T cell response to tumor associated antigens (TAAs) that correlated with protection from distal tumor growth in mice. In the current study we show that a fully synthetic, α-Gal glycolipid-like small molecule, AGI-134, displays potent anti-tumor activity by engaging the cellular and humoral immune system against TAAs. Methods: in vitro and in vivo studies. Results: AGI-134 inserts into the plasma membranes of mouse and human cancer cells in vitro. Anti-Gal IgM and IgG bind to the α-Gal labeled cancer cells and mediate an anti-cancer cell response via complement dependent cytotoxicity, antibody dependent cellular cytotoxicity, and cancer cell phagocytosis by antigen presenting cells in vitro. In anti-Gal producing α-1,3-galactosyltransferase knockout (GT KO) mice, intratumorally (IT) administered AGI-134 greatly inhibits the growth of untreated distal B16-F10 melanoma lesions in an α-Gal- and anti-Gal-dependent fashion. Moreover, we show evidence that AGI-134 acts synergistically with an anti-programmed cell death 1 receptor (PD-1) antibody. In a PK study in GT KO mice, AGI-134 shows low systemic exposure following IT and subcutaneous (SC) administration. In a non-GLP toxicity study in cynomolgus monkeys, 5 SC or intravenous AGI-134 doses ranging from 2-50 mg/kg/dose were well tolerated. The no-observed-adverse-effect level was considered to be 50 mg/kg SC. Conclusions: We propose that AGI-134 has potential as a new immunotherapy for the treatment of solid tumors. The data suggest that AGI-134 may be an excellent combination partner for checkpoint inhibitors in treating cancer. Currently, the drug is being prepared for a Phase I/II clinical trial.


  • Anti‐Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits

    by Uri Galili

    Summary: Anti‐Gal is the most abundant natural antibody in humans, constituting ~ 1% of immunoglobulins. Anti‐Gal is naturally produced also in apes and Old World monkeys. The ligand of anti‐Gal is a carbohydrate antigen called the ‘α‐gal epitope’ with the structure Galα1‐3Galβ1‐4GlcNAc‐R. The α‐gal epitope is present as a major carbohydrate antigen in non‐primate mammals, prosimians and New World monkeys. Anti‐Gal can contributes to several immunological pathogeneses. Anti‐Gal IgE produced in some individuals causes allergies to meat and to the therapeutic monoclonal antibody cetuximab, all presenting α‐gal epitopes. Aberrant expression of the α‐gal epitope or of antigens mimicking it in humans may result in autoimmune processes, as in Graves' disease. α‐Gal epitopes produced by Trypanosoma cruzi interact with anti‐Gal and induce ‘autoimmune like’ inflammatory reactions in Chagas' disease. Anti‐Gal IgM and IgG further mediate rejection of xenografts expressing α‐gal epitopes. Because of its abundance, anti‐Gal may be exploited for various clinical uses. It increases immunogenicity of microbial vaccines (e.g. influenza vaccine) presenting α‐gal epitopes by targeting them for effective uptake by antigen‐presenting cells. Tumour lesions are converted into vaccines against autologous tumour‐associated antigens by intra‐tumoral injection of α‐gal glycolipids, which insert into tumour cell membranes. Anti‐Gal binding to α‐gal epitopes on tumour cells targets them for uptake by antigen‐presenting cells. Accelerated wound healing is achieved by application of α‐gal nanoparticles, which bind anti‐Gal, activate complement, and recruit and activate macrophages that induce tissue regeneration. This therapy may be of further significance in regeneration of internally injured tissues such as ischaemic myocardium and injured nerves.


  • Discovery of the natural anti‐Gal antibody and its past and future relevance to medicine

    by Uri Galili

    This is a personal account of the discovery of the natural anti‐Gal antibody, the most abundant natural antibody in humans, the reciprocal distribution of this antibody and its ligand the α‐gal epitope in mammals and the immunological barrier this antibody has formed in porcine to human xenotransplantation. This barrier has been overcome in the recent decade with the generation of α1,3‐galactosyltransferase gene‐knockout pigs. However, anti‐Gal continues to be relevant in medicine as it can be harnessed for various therapeutic effects. Anti‐Gal converts tumor lesions injected with α‐gal glycolipids into vaccines that elicit a protective anti‐tumor immune response by in situ targeting of tumor cells for uptake by antigen‐presenting cells. This antibody further accelerates wound and burn healing by interaction with α‐gal nanoparticles applied to injured areas and induction of rapid recruitment and activation of macrophages. Anti‐Gal/α‐gal nanoparticle immune complexes may further induce rapid recruitment and activation of macrophages in ischemic myocardium and injured nerves, thereby inducing tissue regeneration and prevention of fibrosis.


  • Open Access

    In situ conversion of tumors into autologous tumor-associated antigen vaccines by intratumoral injection of α-gal glycolipids

    by Uri Galili

    The immunogenicity of autologous tumor-associated antigens (TAAs) is markedly increased upon the intratumoral injection of α-gal glycolipids, which insert into tumor cell membranes. The binding of ...


    • 1 September 2012
      • Vol. 32  (9) , 3861-8

    Cancer immunotherapy by intratumoral injection of α-gal glycolipids.

    by Giles F Whalen, Mary Sullivan, Bilal Piperdi, Wahid Wasseff, Uri Galili

    AIM/ BACKGROUND: To determine the feasibility and safety of intratumoral α-gal glycolipids injection for conversion of human tumors into autologous Tumor Associated Antigens (TAA) vaccine. α-Gal glycolipids bind anti-Gal--the most abundant antibody in humans. Pre-clinical studies indicated that injected α-gal glycolipids insert into tumor cell membranes, bind anti-Gal and target tumor cells to Antigen Presenting Cells, thereby converting tumors into autologous TAA vaccines. We hypothesized that α-gal glycolipids might have similar utility in humans. Eleven patients with advanced solid tumors received one intratumoral injection of 0.1 mg, 1 mg, or 10 mg α-gal glycolipids. The primary endpoint was dose-limiting toxicity (DLT) within 4 weeks. Secondary endpoints included long-term toxicity, autoimmunity, radiological tumor response and survival. There were no DLT and no clinical or laboratory evidence of autoimmunity, or any other toxicity. Few patients had an unexpectedly long survival. Intratumoral injection of α-gal glycolipids is feasible and safe for inducing a protective anti-tumor immune response.


  • Induced Anti-Non Gal Antibodies in Human Xenograft Recipients

    by Uri Galili

    Anti-non gal antibodies are produced in xenograft recipients against multiple xenogeneic antigens. Studies in monkeys transplanted with pig organs lacking α-gal epitopes have suggested that anti-non gal antibodies mediate acute and chronic rejection of xenografts. This overview describes studies of these antibodies in patients who received xenografts and includes (1) an ovarian carcinoma patient receiving three intraperitoneal infusions of mouse fibroblasts in a gene therapy study, (2) orthopedic patients with torn anterior cruciate ligament replaced by a ligament made of pig patellar tendon, and (3) diabetic patients receiving fetal pig islet cell clusters xenograft together with a kidney allograft. Anti-non gal antibodies were found to be continuously produced as long as the xenograft was present in the recipient and were directed against a large number of pig proteins. Monitoring the immune response in the recipient of mouse fibroblasts indicated that the production of anti-non gal antibodies is much slower than that of the anti-Gal antibody, suggesting that they are generated by multiple B-cell clones, each initially comprising relatively few cells. Potent immunosuppression to prevent allograft rejection does not fully inhibit the production of anti-non gal antibodies. Much of this antibody response seems to be due to the differences in amino acid sequences between pig and human orthologous proteins as a result of evolutionary mutations. Overcoming the anti-non gal antibody barrier will require immunosuppressive agents that preferentially inhibit this immune response while maintaining protection against pathogens, or alternatively development of methods for induction of immune tolerance to xenogeneic pig antigens.


  • Open Access

    Conversion of Tumors into Autologous Vaccines by Intratumoral Injection ofα-Gal Glycolipids that Induce Anti-Gal/α-Gal Epitope Interaction

    by Uri Galili

    Anti-Gal is the most abundant antibody in humans, constituting 1% of immunoglobulins. Anti-Gal binds specificallyα-gal epitopes (Galα1-3Galβ1-4GlcNAc-R). Immunogenicity of autologous tumor associated antigens (TAA) is greatly increased by manipulating tumor cells to expressα-gal epitopes and bind anti-Gal. Glycolipids withαgal epitopes (α-gal glycolipids) injected into tumors insert into the tumor cell membrane. Anti-Gal binding to the multiple α-gal epitopesde novopresented on the tumor cells results in targeting of these cells to APC via the interaction between the Fc portion of the bound anti-Gal and Fcγ; receptors on APC. The APC process and present immunogenic TAA peptides and thus, effectively activate tumor specific CD4+ helper T cells and CD8+ cytotoxic T cells which destroy tumor cells in micrometastases. The induced immune response is potent enough to overcome immunosuppression by Treg cells. A phase I clinical trial indicated thatα-gal glycolipid treatment has no adverse effects. In addition to achieving destruction of micrometastases in cancer patients with advance disease,α-gal glycolipid treatment may be effective as neo-adjuvant immunotherapy. Injection ofα-gal glycolipids into primary tumors few weeks prior to resection can induce a protective immune response capable of destroying micrometastases expressing autologous TAA, long after primary tumor resection.


  • Open Access

    Rapid Recruitment and Activation of Macrophages by Anti-Gal/α-Gal Liposome Interaction Accelerates Wound Healing

    by Kim M. Wigglesworth, Waldemar J. Racki, Rabinarayan Mishra, Eva Szomolanyi-Tsuda, Dale L. Greiner, Uri Galili

    Macrophages are pivotal in promoting wound healing. We hypothesized that topical application of liposomes with glycolipids that carry Galα1-3Galβ1-4GlcNAc-R epitopes (α-gal liposomes) on wounds may accelerate the healing process by rapid recruitment and activation of macrophages in wounds. Immune complexes of the natural anti-Gal Ab (constituting ∼1% of Ig in humans) bound to its ligand, the α-gal epitope on α-gal liposomes would induce local activation of complement and generation of complement chemotactic factors that rapidly recruit macrophages. Subsequent binding of the Fc portion of anti-Gal coating α-gal liposomes to FcγRs on recruited macrophages may activate macrophage genes encoding cytokines that mediate wound healing. We documented the efficacy of this treatment in α1,3galactosyltrasferase knockout mice. In contrast to wild-type mice, these knockout mice lack α-gal epitopes and can produce the anti-Gal Ab. The healing time of excisional skin wounds treated with α-gal liposomes in these mice is twice as fast as that of control wounds. Moreover, scar formation in α-gal liposome-treated wounds is much lower than in physiologic healing. Additional sonication of α-gal liposomes resulted in their conversion into submicroscopic α-gal nanoparticles. These α-gal nanoparticles diffused more efficiently in wounds and further increased the efficacy of the treatment, resulting in 95–100% regeneration of the epidermis in wounds within 6 d. The study suggests that α-gal liposome and α-gal nanoparticle treatment may enhance wound healing in the clinic because of the presence of high complement activity and high anti-Gal Ab titers in humans.


  • Open Access

    In Situ Conversion of Melanoma Lesions into Autologous Vaccine by Intratumoral Injections of α-gal Glycolipids

    by Uri Galili, Mark R. Albertini, Paul M. Sondel, Kim Wigglesworth, Mary Sullivan, Giles F. Whalen

    Autologous melanoma associated antigens (MAA) on murine melanoma cells can elicit a protective anti-tumor immune response following a variety of vaccine strategies. Most require effective uptake by antigen presenting cells (APC). APC transport and process internalized MAA for activation of anti-tumor T cells. One potential problem with clinical melanoma vaccines against autologous tumors may be that often tumor cells do not express surface markers that label them for uptake by APC. Effective uptake of melanoma cells by APC might be achieved by exploiting the natural anti-Gal antibody which constitutes ~1% of immunoglobulins in humans. This approach has been developed in a syngeneic mouse model using mice capable of producing anti-Gal. Anti-Gal binds specifically to α-gal epitopes (Galα1-3Galα1-4GlcNAc-R). Injection of glycolipids carrying α-gal epitopes (α-gal glycolipids) into melanoma lesions results in glycolipid insertion into melanoma cell membranes, expression of α-gal epitopes on the tumor cells and binding of anti-Gal to these epitopes. Interaction between the Fc portions of bound anti-Gal and Fcγ receptors on APC induces effective uptake of tumor cells by APC. The resulting anti-MAA immune response can be potent enough to destroy distant micrometastases. A clinical trial is now open testing effects of intratumoral α-gal glycolipid injections in melanoma patients.


  • Accelerated healing of skin burns by anti-Gal/α-gal liposomes interaction

    by Uri Galili, Kim Wigglesworth, Ussama M. Abdel-Motal